Boehringer Ingelheim presents phase III results demonstrating clinical equivalence of adalimumab biosimilar candidate to HUMIRA®

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®.....»»

Cyltezo®, adalimumab biosimilar from Boehringer Ingelheim, approved in Europe for the treatment of multiple chronic inflammatory diseases.....»»

Boehringer Ingelheim receives positive CHMP opinion for adalimumab biosimilar CYLTEZO®.....»»

Boehringer Ingelheim initiates Phase IIa study of compound acquired from Pharmaxis in debilitating liver disease NASH.....»»

Final Phase III Study Results Confirm Benefit of Praxbind® as Reversal Agent for Pradaxa® Patients in Emergency Situations.....»»

Lupin JV announces outcome of Phase III study for biosimilar, Etanercept.....»»

Lupin JV announces outcome of Phase III study for biosimilar, Etanercept.....»»

Glenmark Pharma presents preliminary biomarker data on GBR 1302.....»»

Glenmark Pharma announces results from phase 3 safety study evaluating Ryaltris.....»»

Key sub-analyses of RE-DUAL PCI™ showed large reductions in the incidence of bleeding complications if Pradaxa® (dabigatran etexilate) dual therapy was used instead of warfarin triple therapy.....»»

Takeda Presents Updated Results from Pivotal Phase 2 ALTA Trial of ALUNBRIG™ (brigatinib) in ALK-Positive Non-Small Cell Lung Cancer.....»»

Glenmark’s dermatitis molecule displays positive results in phase-2a trial.....»»

Takeda and Seattle Genetics Announce Positive Results from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma.....»»

Encouraging Phase II survival data for nintedanib in malignant pleural mesothelioma presented at ASCO 2017.....»»

PMI’s Latest Clinical Results: Findings Add to Extensive Evidence Package on Risk Reduction.....»»

Kemwell Biopharma Selected to Manufacture the Monoclonal Antibody Drug Substance For a US Phase 3 Clinical Trial.....»»

Results of Phase III RELEVANCE Study Comparing REVLIMID plus Rituximab (R2) Versus Rituximab Plus Chemotherapy in Patients with Previously Untreated Follicular Lymphoma to be Presented at ASCO 2018.....»»

Results of Phase III OPTIMISMM Study Presented at ASCO 2018 Showed the PVd Triplet Improved PFS in Early Lines of Relapsed or Refractory Multiple Myeloma.....»»

Deshhit: By-poll results has set the stage for 2019 general elections - Zee News.....»»

In this era of personalised medicine, are big clinical trials relevant?.....»»